313 related articles for article (PubMed ID: 18211131)
1. Gender differences in 2 clinical trials of adults with attention-deficit/hyperactivity disorder: a retrospective data analysis.
Robison RJ; Reimherr FW; Marchant BK; Faraone SV; Adler LA; West SA
J Clin Psychiatry; 2008 Feb; 69(2):213-21. PubMed ID: 18211131
[TBL] [Abstract][Full Text] [Related]
2. Emotional dysregulation in adult ADHD and response to atomoxetine.
Reimherr FW; Marchant BK; Strong RE; Hedges DW; Adler L; Spencer TJ; West SA; Soni P
Biol Psychiatry; 2005 Jul; 58(2):125-31. PubMed ID: 16038683
[TBL] [Abstract][Full Text] [Related]
3. Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database.
De Bruyckere K; Bushe C; Bartel C; Berggren L; Kan CC; Dittmann RW
CNS Drugs; 2016 Jun; 30(6):541-58. PubMed ID: 27224994
[TBL] [Abstract][Full Text] [Related]
4. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
[TBL] [Abstract][Full Text] [Related]
5. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.
Simpson D; Plosker GL
Drugs; 2004; 64(2):205-22. PubMed ID: 14717619
[TBL] [Abstract][Full Text] [Related]
6. Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder.
Simpson D; Plosker GL
CNS Drugs; 2004; 18(6):397-401. PubMed ID: 15089111
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials.
Asherson P; Bushe C; Saylor K; Tanaka Y; Deberdt W; Upadhyaya H
J Psychopharmacol; 2014 Sep; 28(9):837-46. PubMed ID: 25035246
[TBL] [Abstract][Full Text] [Related]
8. Psychometric properties of the Wender-Reimherr Adult Attention Deficit Disorder Scale.
Marchant BK; Reimherr FW; Robison D; Robison RJ; Wender PH
Psychol Assess; 2013 Sep; 25(3):942-50. PubMed ID: 23647041
[TBL] [Abstract][Full Text] [Related]
9. Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial.
Wietecha L; Williams D; Shaywitz S; Shaywitz B; Hooper SR; Wigal SB; Dunn D; McBurnett K
J Child Adolesc Psychopharmacol; 2013 Nov; 23(9):605-13. PubMed ID: 24206099
[TBL] [Abstract][Full Text] [Related]
10. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.
Adler LA; Spencer T; Brown TE; Holdnack J; Saylor K; Schuh K; Trzepacz PT; Williams DW; Kelsey D
J Clin Psychopharmacol; 2009 Feb; 29(1):44-50. PubMed ID: 19142107
[TBL] [Abstract][Full Text] [Related]
11. Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double-Blind, Placebo-Controlled, Randomized Trials.
Wietecha LA; Clemow DB; Buchanan AS; Young JL; Sarkis EH; Findling RL
CNS Neurosci Ther; 2016 Jul; 22(7):546-57. PubMed ID: 26922462
[TBL] [Abstract][Full Text] [Related]
12. Long-term open-label response to atomoxetine in adult ADHD: influence of sex, emotional dysregulation, and double-blind response to atomoxetine.
Marchant BK; Reimherr FW; Halls C; Williams ED; Strong RE; Kondo D; Soni P; Robison RJ
Atten Defic Hyperact Disord; 2011 Sep; 3(3):237-44. PubMed ID: 21442440
[TBL] [Abstract][Full Text] [Related]
13. Validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale in European patients: comparison with patients from the USA.
Brod M; Adler LA; Lipsius S; Tanaka Y; Heinloth AN; Upadhyaya H
Atten Defic Hyperact Disord; 2015 Jun; 7(2):141-50. PubMed ID: 25563210
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis.
Cheng JY; Chen RY; Ko JS; Ng EM
Psychopharmacology (Berl); 2007 Oct; 194(2):197-209. PubMed ID: 17572882
[TBL] [Abstract][Full Text] [Related]
15. A randomized, waiting list-controlled 12-week trial of atomoxetine in adults with ADHD.
Sobanski E; Sabljic D; Alm B; Baehr C; Dittmann RW; Skopp G; Strohbeck-Kuehner P
Pharmacopsychiatry; 2012 May; 45(3):100-7. PubMed ID: 22174029
[TBL] [Abstract][Full Text] [Related]
16. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
[TBL] [Abstract][Full Text] [Related]
17. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.
Kelsey DK; Sumner CR; Casat CD; Coury DL; Quintana H; Saylor KE; Sutton VK; Gonzales J; Malcolm SK; Schuh KJ; Allen AJ
Pediatrics; 2004 Jul; 114(1):e1-8. PubMed ID: 15231966
[TBL] [Abstract][Full Text] [Related]
18. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine.
Adler LA; Sutton VK; Moore RJ; Dietrich AP; Reimherr FW; Sangal RB; Saylor KE; Secnik K; Kelsey DK; Allen AJ
J Clin Psychopharmacol; 2006 Dec; 26(6):648-52. PubMed ID: 17110824
[TBL] [Abstract][Full Text] [Related]
19. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD.
Rösler M; Retz W; Fischer R; Ose C; Alm B; Deckert J; Philipsen A; Herpertz S; Ammer R
World J Biol Psychiatry; 2010 Aug; 11(5):709-18. PubMed ID: 20353312
[TBL] [Abstract][Full Text] [Related]
20. Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder.
Takahashi M; Goto T; Takita Y; Chung SK; Wang Y; Gau SS
Asia Pac Psychiatry; 2014 Mar; 6(1):62-70. PubMed ID: 23857916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]